Last reviewed · How we verify
Amisulpride add-on
Amisulpride add-on is a Atypical antipsychotic Small molecule drug developed by National Health Research Institutes, Taiwan. It is currently FDA-approved for Augmentation therapy for major depressive disorder with inadequate response to antidepressants, Augmentation therapy for schizophrenia or other psychotic disorders.
Amisulpride is a selective dopamine D2/D3 receptor antagonist that blocks dopamine signaling in the brain to reduce psychotic symptoms and improve mood.
Amisulpride is a selective dopamine D2/D3 receptor antagonist that blocks dopamine signaling in the brain to reduce psychotic symptoms and improve mood. Used for Augmentation therapy for major depressive disorder with inadequate response to antidepressants, Augmentation therapy for schizophrenia or other psychotic disorders.
At a glance
| Generic name | Amisulpride add-on |
|---|---|
| Sponsor | National Health Research Institutes, Taiwan |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Dopamine D3 receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Amisulpride preferentially antagonizes dopamine receptors in the mesolimbic and mesocortical pathways at low doses, with activity at D2 receptors predominating. At higher doses, it also blocks D3 receptors. As an add-on therapy, it is used to augment antidepressant or antipsychotic effects in patients with inadequate response to monotherapy.
Approved indications
- Augmentation therapy for major depressive disorder with inadequate response to antidepressants
- Augmentation therapy for schizophrenia or other psychotic disorders
Common side effects
- Akathisia
- Parkinsonism
- Prolactin elevation
- Weight gain
- Insomnia
- Anxiety
Key clinical trials
- Enhancing Recovery in Early Schizophrenia (PHASE2)
- Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT) (PHASE3)
- Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia (PHASE2)
- Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amisulpride add-on CI brief — competitive landscape report
- Amisulpride add-on updates RSS · CI watch RSS
- National Health Research Institutes, Taiwan portfolio CI
Frequently asked questions about Amisulpride add-on
What is Amisulpride add-on?
How does Amisulpride add-on work?
What is Amisulpride add-on used for?
Who makes Amisulpride add-on?
What drug class is Amisulpride add-on in?
What development phase is Amisulpride add-on in?
What are the side effects of Amisulpride add-on?
What does Amisulpride add-on target?
Related
- Drug class: All Atypical antipsychotic drugs
- Target: All drugs targeting Dopamine D2 receptor, Dopamine D3 receptor
- Manufacturer: National Health Research Institutes, Taiwan — full pipeline
- Therapeutic area: All drugs in Psychiatry
- Indication: Drugs for Augmentation therapy for major depressive disorder with inadequate response to antidepressants
- Indication: Drugs for Augmentation therapy for schizophrenia or other psychotic disorders
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing